CatalystWireBeta

Result of AGM

In brief · summary, not quotable

Hemogenyx Pharmaceuticals plc announced that all resolutions were passed at its Annual General Meeting, with strong support for the adoption of the 2025 accounts (96.22% for), re-appointment of auditors PKF Littlejohn LLP (95.73% for), and the re-appointment of directors Vladislav Sandler (95.68% for), Sir Marc Feldmann (95.66% for), and Peter Redmond (81.31% for). The company also secured shareholder approval for the directors' remuneration report (93.00% for), authority to allot shares (87.03% for), and to dis-apply pre-emption rights (83.61% for).

Full announcement

Select text to share a quote on X · sign in to keep highlights & notes in your HEMO notes

Hemogenyx Pharmaceuticals plc is pleased to announce that, at the Annual General Meeting ("AGM") held yesterday afternoon, all resolutions were duly passed by shareholders. The numbers of proxy votes for each resolution submitted prior to the meeting are presented below.

Proxy Voting Results

Ordinary ResolutionsVotes for% of votes cast forVotes Against% of votes cast againstTotal votes castTotal votes cast as % of ISC (1)Votes with-held (2)
1. To receive and adopt the Company's annual accounts for the financial year ended 31 December 2025 together with the directors' reports and auditor's report on those accounts1,457,30096.225,9660.391,514,59222.2716,829
2. To approve the Directors' Remuneration Report1,307,71093.0047,1253.351,406,16120.68125,260
3. To re-appoint PKF Littlejohn LLP as auditors1,441,69895.7313,0110.861,506,03522.1525,386
4. To authorise the Audit Committee to determine the level of the auditor's remuneration1,349,32995.788,1500.581,408,80520.72122,616
5. To authorise the re-appointment of Vladislav Sandler1,454,81095.6814,3980.951,520,53422.3610,887
6. To authorise the re-appointment of Alexis Sandler1,371,16391.1481,9315.451,504,42022.1227,001
7. To authorise the re-appointment of Sir Marc Feldmann1,454,14995.6614,5910.961,520,06622.3511,355
8. To authorise the re-appointment of Peter Redmond1,224,47781.31230,10815.281,505,91122.1525,510
9. To grant the Directors authority to allot and issue shares and grant rights to subscribe for shares in the Company for the purposes of Section 551 of the Act.1,242,85387.03133,8349.371,428,01321.00103,378
Special ResolutionsVotes for% of votes cast forVotes against% of votes cast againstTotal votes castTotal votes cast as % of ISC (1)Votes with-held (2)
10. To dis-apply the statutory rights of pre-emption in respect of the allotment of equity securities for cash under Section 561(1) of the Act.1,195,85183.61183,06812.801,430,24521.03101,176
11. To authorise the Directors to call a general meeting of the Company, other than an annual general meeting,1,409,24192.6161,1064.021,521,67322.389,748
  • The Company's issued share capital ("ISC") on 26 June 2026, being the date on which members had to be entered in the register of members of the Company in order to be entitled to attend and vote at the meeting, was 6,799,961 ordinary shares.
  • A 'vote withheld' in respect of any resolution is not a vote in law and is not counted in the calculation of the proportion of the votes for and against it.

A copy of the resolutions passed has been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.

Share this quote

Quote card
Post on X WhatsApp Download image

The link opens this announcement with the quote highlighted. Quotes are checked against the original text.

Add a note